ABthrax(TM): Meeting Contract Milestones
HGS has met all milestones to date under its contract with the U.S. Government to supply 20,000 doses of ABthrax (raxibacumab) to the Strategic National Stockpile. The Company is working to conduct the additional clinical and laboratory studies required to support the filing of a Biologics License Application (BLA), and is on track to begin delivery to the stockpile in 2008. HGS expects to receive $165 million under the contract, with most of the revenue to come in 2008 and with the remainder to come when ABthrax is licensed by the FDA.
TRAIL Receptor Antibodies: Clinical and Preclinical Results
In October 2007, HGS presented new clinical and preclinical evidence of the anti-tumor activity and tolerability of the Company's TRAIL receptor antibodies for the treatment of cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The results of a Phase 1b trial demonstrated that HGS-ETR2 (lexatumumab) was safe and well tolerated in combination with four different standard chemotherapy regimens in patients with a wide range of cancer types. Objective responses were reported for two patients, and stable disease was observed in 22 patients.
The Company also presented preclinical data demonstrating that HGS-ETR1 (mapatumumab) and HGS-ETR2 in combination with chemotherapy synergistically enhanced anti-tumor activity in cholangiocarcinoma (cancer of the bile ducts). In a xenograft model of cholangiocarcinoma, the results demonstrated that HGS- ETR1 and either co-treatment or pre-treatment with cisplatin and gemcitabine were more effective than chemotherapy or HGS-ETR1 alone.
HGS is currently enrolling a randomized Phase 2 trial of H
|SOURCE Human Genome Sciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved